vimarsana.com

Latest Breaking News On - Nasdaq casi - Page 3 : vimarsana.com

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews com

StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report sent to investors on Monday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright boosted their target price on shares of CASI Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy […]

StockNews com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI)

StockNews.com initiated coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright lifted their price objective on CASI Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy rating in a research report on […]

CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews com

StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright raised their price objective on CASI Pharmaceuticals from $10.00 to $12.00 and gave the company a buy rating in a […]

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews com

StockNews.com initiated coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note released on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright boosted their price objective on shares of CASI Pharmaceuticals from $10.00 to $12.00 and gave the company a buy rating in a […]

CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews com

StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a report released on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright raised their price objective on shares of CASI Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy rating in a […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.